Recombinant human soluble thrombomodulin as an anticoagulation therapy improves recurrent miscarriage and fetal growth restriction due to placental insufficiency – The leading cause of preeclampsia

Takumi Sano(Osaka Medical and Pharmaceutical University), Masahide Ohmichi(Osaka University of Pharmaceutical Sciences), Yoko Nagayasu(Osaka Medical and Pharmaceutical University), Daisuke Fujita(Kagoshima University), Yoshito Terai(Osaka Medical and Pharmaceutical University), Masami Hayashi(Yamagata University), Atsuko Okamoto(Osaka Medical and Pharmaceutical University), Atsushi Daimon(Osaka Medical and Pharmaceutical University), Misa Nunode(Osaka University of Pharmaceutical Sciences)
Placenta
March 25, 2018
10.1016/j.placenta.2018.03.006
Cited by 15

Related Papers

Estrogen Induces the Akt-dependent Activation of Endothelial Nitric-oxide Synthase in Vascular Endothelial Cells
|Journal of Biological Chemistry|2001|387
Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin.
|PubMed|2000|249
Inhibition of NFκB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models
|Journal of Biological Chemistry|2004|212
Estrogen Suppresses Transcription of Lipoprotein Lipase Gene
|Journal of Biological Chemistry|2000|209
Inhibition of Extracellular Signal-regulated Protein Kinase or c-Jun N-terminal Protein Kinase Cascade, Differentially Activated by Cisplatin, Sensitizes Human Ovarian Cancer Cell Line
|Journal of Biological Chemistry|1999|174